The liver is known to clear and detoxify circulating lipopolysaccharide (LPS). To characterize the molecules involved in this process in the liver, we attempted to purify mouse liver protein(s) that can interact with lipid A, a biologically active portion of LPS. By partially purifying the inactivating activity against a synthetic lipid A analog, we observed the enrichment of a 45-kDa protein in the active fractions. The internal amino acid sequences of the protein were identical with those of argininosuccinate synthase (EC 6.3.4.5). To examine whether argininosuccinate synthase can interact with lipid A, we purified the enzyme from mouse liver and found the co-elevation of the specific enzyme activity and specific lipid A-inactivating activity, indicating that argininosuccinate synthase is the major lipid A-interacting protein in liver. Argininosuccinate synthase also inhibited the biological activities (macrophage activation and Limulus test) of natural lipid A and rough-type LPS but not smooth-type LPS. The enzyme activity was inhibited by lipid A and rough-type LPS and also by smooth-type LPS. Native gel electrophoresis of a mixture of argininosuccinate synthase and LPS and immunoprecipitation of a mixture of argininosuccinate synthase and [ 3 H]-LPS with anti-argininosuccinate synthase antiserum showed that argininosuccinate synthase stably bound lipid A and LPS. These findings, together, indicate that argininosuccinate synthase can effectively bind LPS in the liver.
INTRODUCTION
Innate immunity recognizes products of pathogenic organisms and mounts an early response including the complement activation cascade, liberation of lipid metabolites, generation of active oxygen species and cytokine production, which together mount the host defense against invading pathogens. The magnitude and localization of these responses is tightly regulated and the loss or deficiency of restraint mechanisms renders the host susceptible to the lethal toxicity of uncontrolled systemic responses. In fact, the introduction of Gramnegative bacterial cell-wall component lipopolysaccharide (LPS) or its active component, lipid A, into the animals is known to generate endotoxic symptoms in diverse organs, including fever, nausea, hypotension, lassitude, and diarrhea, which occasionally result in death of the host (reviewed by Nowotny 1 and by Morrison and Ryan 2 ) . Escalated systemic responses which threaten the host are not restricted to artificially generated conditions but occur in pathological situations of animals and humans. Numerous animal and human studies have clarified that bacterial components and indigenous bacterial flora themselves in the gastrointestinal tract can translocate from inside the lumen to extraintestinal sites; this phenomenon is known as bacterial translocation. Mucosal damage owing to ischemia/reperfusion injury and oxygen stress can result in gut barrier dysfunction, which allows translocation of bacteria and LPS into the mesenteric lymph and then the systemic circulation resulting in massive systemic inflammatory responses. 3, 4 Therefore, tolerance of the host response to LPS, inactivation of LPS activities and LPS clearance from the circulation are tremendously important for controlling the highly sensitive reactions of the innate immunity system to the bacterial components.
Regarding the cellular response to LPS of leukocytes, it has been clarified that Toll-like receptor 4 (TLR4) together with MD-2 on the cell surface of macrophages, monocytes and polymorphonuclear cells are responsible for the recognition of LPS. 5 The recognition of LPS by TLR4 plus MD-2 is augmented by another cell surface GPIanchored molecule, CD14. 6 The binding of a plasma protein, LPS-binding protein (LBP), to the cytoplasmic membrane of leukocytes presumably in a manner of the intercalation into the lipid matrix is also involved in the recognition of LPS 7 and likely results in the formation of a ternary complex with CD14 to enhance the response mediated by TLR4-MD-2 complexes. 8 These recognition processes can be impeded and thus regulated by other proteins that potentially bind to LPS. For instance, bactericidal/ permeability increasing protein (BPI) and CAP18, which are proteins secreted from the granules of neutrophils, bind to LPS and suppress the cellular response to LPS. 9, 10 Lactoferrin, a glycoprotein found in milk and also secreted from granules of neutrophils, has been reported to bind to LPS and attenuate its activity. 11 Serum amyloid P component binds to LPS and inhibits LPS-induced responses in macrophages. 12 Hemoglobin and its heme-depleted protein, globin, modulate LPS activity by binding to LPS. 13 These proteins are thought to control the magnitude of the LPS response and restrain inflammatory reactions locally in tissues infected by Gram-negative bacteria. The mucus of the gastrointestinal tract and the pulmonary surfactant contain proteins and peptides that bind to LPS and these molecules are thought to modulate the inflammatory reactions in those tissues when they are exposed to enteric and airway bacteria. [14] [15] [16] Therefore, the response of innate immunity to LPS is controlled positively and negatively by LPS-binding molecules in the plasma and bacterial infection sites.
In addition to detoxification of circulating LPS, responses to LPS can be regulated in vivo by cellular clearance of LPS and related molecules. The liver is known to be a major organ involved in clearing circulating LPS, and Kupffer cells and hepatocytes both contribute to the mechanism through different recognition systems. CD14 on the cell surface in collaboration with LBP may be responsible for the binding and internalization of LPS independently of cellular responses to LPS. 17, 18 Internalization of LPS into hepatocytes is mediated by the association of LPS with plasma lipoprotein and recognition of the complex by LDL receptor and LDL receptor-related protein (LRP) on the cell surface, resulting in excretion of LPS into the bile. [19] [20] [21] The pathological significance of the clearance of circulating LPS by the liver is supported by the correlation between liver dysfunction and the occurrence of bacterial translocation. For instance, obstructive jaundice 22 and partial hepatectomy 23 were reported to provoke bacterial translocation in experimental animals. Linkage of hepatic dysfunction and low clearance of LPS perfused into the liver was also reported in a pancreatitis model involving in vivo and ex vivo experiments. 24 To elucidate the molecular mechanism of the involvement of the liver in the clearance of LPS, we examined the existence of LPS-interacting molecules in liver extracts from mice and found a factor(s) that had protein-like properties and that inhibited biological activities of lipid A. 25 The factor dose-dependently suppressed TNF-triggering activity and Limulus amebocyte lysate activation of lipid A but showed no effect on macrophage functions. Binding experiments showed the direct interaction of [ 14 C]labeled lipid A analog with the factor immobilized on a plate. Failure to detect degradation products of lipid A indicated the lack of involvement of enzymatic activity. These findings suggest that the liver contains a protein(s) that likely interacts with the lipid A portion of LPS, and that this interferes with biological activities of LPS and the protein(s) may be involved in the protective function of liver against the gastrointestine-derived and systemically circulating LPS.
In the present study, we attempted to characterize the lipid A-inactivating protein(s) from mouse liver extract and obtained a semi-purified lipid A-inactivating fraction, in which a 45-kDa protein was enriched. The amino acid sequence analysis of the 45-kDa protein revealed, unexpectedly, that the protein was argininosuccinate synthase, suggesting that this protein was a candidate for a lipid Ainactivating protein in liver. To examine this possibility, we purified argininosuccinate synthase from mouse liver. During the purification steps, argininosuccinate synthase enzymatic activity and lipid A-inactivating activity were increased roughly in parallel, indicating that argininosuccinate synthase is the major protein in liver which interacts with bacterial lipid A. Analysis by native gel electrophoresis showed that argininosuccinate synthase can bind bacterial lipid A and LPS.
MATERIALS AND METHODS

Reagents
Lipopolysaccharide (LPS) from Escherichia coli O111:B4 strain (S-LPS: smooth-type LPS), LPS from E. coli J5 (Rc) strain (R-LPS: rough-type LPS), LPS from E. coli K12 LCD25 strain (LPS-K12), lipid A from Salmonella minnesota 595 (MPL: monophosphoryl lipid A) and lipid A from E. coli K12, D31m4 strain (DPL: diphosphoryl lipid A) were bought from List Biological Lab., Inc. (California, USA), dissolved at 2-5 mg/ml in 0.5% triethylamine by sonication, and stored in aliquots at -80°C. [ 3 H]-Labeled LPS ( 3 H-LPS) from E. coli K12 LCD25 strain (34.7 Bq/mg) was also obtained from List Biological Lab. and dissolved at 0.2 mg/ml in 0.5% triethylamine by sonication. ONO-4007, a synthesized lipid A analog (sodium 2-deoxy-2-[3S-(9-phenylnonanoyl-oxy) tetradecanoyl] amino-3-O-(9-phenylnonanoyl)-D-glucopyranose 4-sulfate) was donated from Ono Pharmaceutical Co. Ltd, dissolved at 10 mg/ml in 100% ethanol and stored at -20°C. A synthetic E. colitype lipid A, LA-15-PP (506), was purchased from Daiichi Chemicals Co. Ltd (Tokyo, Japan) and a 0.5 mg/ml solution in 0.025% triethylamine was stored at 4°C. Prior to use of these LPSs and lipid A, the stock solutions were appropriately diluted and sonicated for at least 10 min. Bovine serum albumin (BSA; very low endotoxin), TPCK-trypsin, Staphylococcus aureus V8 protease, and pyrophosphatase from bakers' yeast were from Sigma Chemical Co. (St Louis, MO, USA). Eagle's MEM and RPMI-1640 media were from Nissui Pharmaceutical Co. (Tokyo, Japan). Collagenase from Streptomyces parvulus was a product of Nitta Gelatin Inc. (Osaka, Japan). All buffers and tissue culture media were prepared in pyrogen-free distilled water (Otsuka Pharmaceutical Co. Tokushima, Japan).
Animals and cell lines
Male C3H/He mice and female JW/CSK rabbits were purchased from Japan SLC Co., Ltd (Shizuoka, Japan). L-929, a transformed mouse fibroblast cell line, was passaged in Eagle's MEM supplemented with 5% calf serum (CS) twice a week and used for the in vitro TNF assay.
Procedures for chromatography of mouse liver extract
Liver extract was prepared from mouse as described by our laboratory. 25 Liver extract from 3 mice (8.5 ml, total OD: 101.7) was applied to a column (2.5 x 20 cm) of Phenyl-cellulofine (Seikagaku Co., Ltd, Tokyo, Japan) equilibrated with 25 mM Tris-HCl (pH 7.5), washed with 200 ml of the same buffer and eluted successively with 150 ml of buffer containing 40% ethylene glycol, 3 M urea and 6 M urea in a step-wise manner. After changing the eluting solution to 25 mM Tris-HCl (pH 7.5) with a Sephadex G-25 column, the fractions were assessed for the ability to inactivate the TNF-triggering activity of synthetic lipid A, as described below. The fractions eluted with 6 M urea were pooled and a 2.5-ml portion of the pooled material was loaded on a Sephacryl S-200HR column (28 x 530 mm) and eluted with 25 mM Tris-HCl (pH 7.5) containing 0.154 M NaCl at a flow rate of 0.5 ml/min. All procedures were done at 4°C.
Sequencing of 45-kDa protein
A 2.5-ml (0.7 mg protein) aliquot of the 6 M urea fraction from Phenyl-cellulofine was treated with SDS plus 2-mercaptoethanol and subjected to SDS-PAGE. The position of the 45-kDa protein was ascertained by CBBstaining of small parts of the gel, and this region was excised, cut into pieces of about 1-mm 3 size, and squashed with a microgrinder. Half of the squashed gel was treated with TPCK-trypsin and the other half with Staph. aureus protease. For digestion with TPCKtrypsin, an equal volume of 50 mM Tris-HCl (pH 8.0) containing 8 M urea and 1 µg of TPCK-trypsin was added to the squashed gel. After overnight incubation at 37°C, digestion products were extracted from the gel slurry by spinning several times at 10,000 rpm with a Spin Column Filter (BioRad Laboratory) using the above digestion buffer in which the concentration of urea was decreased by half. Digestion with Staph. aureus V8 protease was carried out similarly, using a digestion buffer of 0.1 M NH 4 HCO 3 (pH 7.8) containing 8 M urea. About 50 µg of peptides were obtained under each set of digestion conditions and the whole extract was subjected to Tricine-SDS-PAGE and electroblotted onto a PVDF membrane. After visualizing by staining with 0.1% Ponceau S in 2% AcOH, membrane portions containing the peptide bands of interest were excised and analyzed by Edman microsequencing, using an automatic amino acid sequencer (Applied Biosystems 477A) according to the manufacturer's protocol. Partial sequences obtained from several peptides were searched for identification or homology to previously sequenced proteins using an online database, SWISS-PROT (<http://www.expasy.ch/tools/scnpsit2.html>).
Purification of argininosuccinate synthase from mouse liver
Argininosuccinate synthase was purified basically by the method for human argininosuccinate synthase from liver reported by Saheki et al. 26 In brief, livers were excised from 20 male mice (C3H/He strain, aged 7-8 weeks) and homogenized in 100 mM Tris-HCl (pH 7.5) containing 1 mM citrulline and 1 mM aspartic acid for stabilization of the enzyme activity. The homogenate was centrifuged at 20,000 g for 100 min at 4°C and the supernatant was subjected to the following steps. After salting-out with 45-55% saturated ammonium sulfate, precipitates obtained were dissolved in 3 ml of 10 mM Tris-HCl (pH 7.5) containing 1 mM citrulline and 1 mM aspartic acid and dialyzed against the same buffer. This entire fraction was then subjected to anion-exchange chromatography on DE-52 (Whatman, 24 x 140 mm column) at a flow rate of about 0.7 ml/min in the same buffer, and flowthrough fractions were pooled and concentrated with Molecut (MCO: 30,000 kDa, Millipore Co., Ltd). The concentrated sample was loaded on a column (17 x 1000 mm) of Sephacryl S-300 HR (Pharmacia) at a flow rate of 0.17 ml/min in 100 mM Tris-HCl (pH 7.5) containing 1 mM citrulline and 1 mM aspartic acid and the first peak fractions were collected. These fractions were then dialyzed against 20 mM HEPES (pH 7.5) containing 1 mM citrulline and 1 mM aspartic acid and subjected to anionexchange chromatography on UNO S-1 (BioRad) at a flow rate of 0.5 ml/min in the same buffer with an increasing concentration of NaCl from 0 to 130 mM. Argininosuccinate synthase was eluted in fractions at approximately 40 mM NaCl. The homogeneity was verified by SDS-PAGE analysis and more than 95% purity was ascertained.
Assay for enzymatic activity of argininosuccinate synthase
The method for measurement of the enzyme activity of argininosuccinate synthase was based on that of Xie and Gross, 27 which measures inorganic phosphate generated by pyrophosphatase added to the reaction mixture from pyrophosphate (PP i ) which is liberated from ATP during the synthesis of argininosuccinate from citrulline and aspartic acid by argininosuccinate synthase. In brief, 8 µl of sample was added to 40 µl of 11.1 mM Tris-HCl (pH 7.5) containing 12 mM MgCl 2 , 40 mM KCl and 10 µl of BSA (reaction buffer) in a 96-well microtiter plate. After the addition of 32 µl of 11.1 mM Tris-HCl (pH 7.5) containing 1 mM ATP and 1 U/ml of pyrophosphatase plus or minus substrates of 1 mM aspartic acid and 12.5 mM citrulline, the plate was incubated at 37°C for 30 or 60 min. For calibrating the concentration of inorganic phosphate (P i ) generated in the reaction, 80 µl of increasing concentrations of KH 2 PO 4 from 0 to 400 µM was added to the plate as standard. The reaction was stopped by adding 20 µl of 5% SDS in water to all wells. After the addition of 100 µl of 24 mg/ml ascorbic acid in ammonium molybdate-H 2 SO 4 solution (1.145 g of ammonium molybdate and 5.95 ml of H 2 SO 4 in 250 ml of water) and further incubation at room temperature for 30-40 min, P i was measured by absorbance at 630 nm. Net argininosuccinate synthase activity was calculated by subtracting the value in the reaction condition without substrates from that with substrates.
Inhibition of the enzyme activity of argininosuccinate synthase by LPS and lipid A was examined as follows. Increasing amounts of LPS and lipid A were added to the UNO-S1 argininosuccinate synthase fraction (final 4 µg/ml) in reaction buffer. After incubation at 37°C for 60 min, the enzyme activity in the mixtures was estimated by the addition of substrate mixture and another incubation at 37°C for 30 min; finally, the concentration of P i generated was measured as described above. The negative control for the background value was prepared by adding SDS solution prior to the addition of substrate mixture. Residual enzyme activity after treatment with LPS or lipid A was calculated as follows. Percentage of control = (experimental P i -background)/(P i without inhibition -background) x 100.
Measurement of biological activities of lipid A and LPS
Macrophage stimulation and Limulus amebocyte lysate (LAL) activation of lipid A were measured as reported from our laboratory. 25 A liver cell suspension was obtained from mice by in situ collagenase perfusion. The Kupffer cell-enriched population (non-parenchymal liver cells) was collected from the liver cell suspension by differential low speed centrifugation. Cells with adherent properties were then selected by incubation in a 96-well plate for 45 min and used as the Kupffer cell fraction. Lipid A or LPS solution in 10 µg/ml BSA in PBS was added at a 1:4 ratio to Kupffer cells in RPMI-1640 medium containing 5% FCS; after 60 min of incubation, the cells were washed with the same culture medium and further cultured for 2 h. Tumor necrosis factor (TNF) secreted in culture supernatants was measured by assessing its cytotoxic activity toward L-929 cells in the presence of 1 µg/ml actinomycin D. After 18 h of culture with Kupffer cell culture supernatant, viable L-929 cells were stained with crystal violet and absorbance at 580 nm was measured. Results were expressed by the decrease of cell viability or TNF secretion calibrated relative to a TNF standard as units/10 5 Kupffer cells (IU/10 5 cells). Although this bioassay is unable to detect TNF at less than 0.5 IU/ml, the levels of TNF released by LPS-stimulated Kupffer cells (1-2 x 10 4 cells in 200 µl/well in this experiment system) were in the measurable range of this method. The LAL activation test was performed by chromogenic determination, using a commercial Toxicolor test LS-20 kit combined with the diazocoupling reagent of DIA-MP (Seikagaku Co., Ltd, Tokyo, Japan), following the manufacturer's recommendations. The extent of the reaction was determined by measuring absorbance at 550 nm minus 630 nm (A 550-630 ).
To examine the inactivation of the biological activities of lipid A and LPS by fractions from liver extract and argininosuccinate synthase, samples were added to lipid A or LPS solution in 10 µg/ml BSA in PBS and the mixtures were incubated at 37°C for 60 min. The biological activities remaining in the mixture were then measured as above.
Electrophoresis and electrotransfer
SDS polyacrylamide gel electrophoresis (SDS-PAGE) of proteins was done using the system of Laemmli 28 and Tricine-SDS-PAGE using the system of Schëgger and von Jagow. 29 Electrotransfer was carried out using a semi-dry and discontinuous buffer system using HorizeBlot AE-6675P/N (Atto Co., Ltd, Japan) as recommended in the manufacturer's manual with a nitrocellulose or PVDF membrane (Sequi-Blot, BioRad Laboratory).
Native PAGE and 2-D native-SDS-PAGE of argininosuccinate synthase and lipid A mixture
Mixtures of argininosuccinate synthase and lipid A or LPS in 11.1 mM Tris-HCl (pH 7.5) were incubated at 37°C for 30 min. The mixture was then analyzed by native PAGE using a 5-20% gradient pre-cast gel (PAGEL NPG-520L, ATTO Co., Ltd, Tokyo, Japan). For further analysis (2-D native-SDS-PAGE), a gel slice (3mm width) from an unstained gel was incubated in SDStreatment equilibrium buffer (62 mM Tris-HCl, 10% glycerol, 5% 2-mercaptoethanol, 2.3% SDS, pH 6.8) for 15 min at room temperature. The gel slice was loaded on another 10% acrylamide gel and SDS-PAGE was carried out in the Laemmli system.
After electrophoresis, the gel was silver-stained with a commercial kit (2D-silver stain-II, Daiichi Pure Chemicals Co., Ltd, Tokyo, Japan) or electrotransfered onto a PVDF membrane and stained with anti-argininosuccinate synthase rabbit serum obtained in our laboratory and a Vectastain ABC kit for rabbit IgG using TMB as a peroxidase substrate (Vector Laboratories, Burlingame, CA, USA).
Preparation of anti-mouse argininosuccinate synthase rabbit serum
Rabbits (n = 3) were immunized intramuscularly with 2 x 300 µg of purified argininosuccinate synthase emulsified with an equal volume of TiterMax Gold (CytRx, Norcross, Georgia). After 4 weeks, a rabbit was selected based on ELISA of its serum and boosted using the same procedure as for the first immunization. Antiserum was prepared 7 weeks after the boost. Antibody generation was measured by ELISA using a plate (Maxisorp, Nunc) coated with argininosuccinate synthase and a Vectastain ABC kit for rabbit IgG. Rabbit serum with elevation of the titer up to 300-fold was obtained. Addition of antiargininosuccinate synthase serum (final 1/100 dilution) to argininosuccinate synthase (4 µg/ml) failed to decrease the enzyme activity, indicating that the antibody obtained has no neutralizing activity (data not shown). The specificity for argininosuccinate synthase was verified by Western blotting of purified argininosuccinate synthase and liver cytosol fractions.
Immunoprecipitation of LPS-bound argininosuccinate synthase by anti-argininosuccinate synthase antiserum
Purified argininosuccinate synthase or crude liver extract was incubated at 37°C for 30 min with 3 H-LPS (4 µg/ml) in Tris-buffered saline (TBS, pH 7.5). Portions of the mixture were reacted with 1/30 diluted anti-argininosuccinate synthase antiserum or pre-immune serum (4°C, 2 h), and incubated by continuous shaking at 4°C for 2 h at a 1:1 ratio with 50% slurry of protein G-Sepharose (Pharmacia Biotech, Uppsala, Sweden) pre-equilibrated with 2 mg/ml BSA in TBS. After washing 5 times with TBS, 3 H-LPS bound in the slurry was dissolved in 5% SDS solution and counted using a liquid scintillation counter (LSC-3000, Aloka, Tokyo, Japan) after the addition of Aquasol II (NEN Research Products, Boston, MA, USA). By estimating the enzyme activity retained by protein G-Sepharose, it was proven that argininosuccinate synthase binds to protein G-Sepharose in an antibody-dependent manner under these experimental conditions (data not shown).
Protein assay
Protein and peptide concentrations were determined by the Bradford method using a commercial reagent (BioRad). BSA was used as a standard.
Statistical analysis
Data are presented as mean ± SD. Results were statistically treated by Student's t-test or Dunnet's method of multiple comparison.
RESULTS
Partial purification of lipid A-inactivating activity from liver extract
Previous protease digestion experiments indicated that protein-like molecule(s) in mouse liver extract bind to lipid A and inactivate its biological activities. 25 To isolate the
Liver AS binds to bacterial LPS and lipid A and inactivates their biological activities 25
protein(s), we attempted to purify the responsible molecules from liver extract by liquid chromatography. In a preliminary experiment, anion-exchange and hydroxyapatite chromatography were found to fail to enrich the active proteins because of low recovery of the activity, presumably owing to adsorption by the resin matrices (data not shown). As the responsible molecules are presumed to interact with an amphiphilic molecule, lipid A, we then attempted to separate the proteins by hydrophobic chromatography using Phenyl-cellulofine. As shown in Table 1 , the lipid A-inactivating activities targeting a synthetic lipid A, ONO-4007, were completely retained Mouse liver extract (8.5 ml) was applied to a Phenyl-cellulofine column and proteins were eluted with buffers containing 40% ethylene glycol, 3 M urea and 6 M urea in a step-wise manner, and protein peak fractions were pooled. After buffer changing with a Sephadex G-25 column, the inhibitory effects of these fractions on TNF-triggering of ONO-4007 were examined. a Total OD was calculated with the formula, A 280 x volume (ml). b Serially diluted fractions in PBS were added to 40 ng/ml ONO-4007 and incubated at 37°C for 60 min. Residual TNF-triggering activities of ONO-4007 were measured as described in Materials and Methods. The half-inhibitory dilution was determined and the ratio of the dilution of each fraction to that of liver extract was expressed as relative activity. Specific activity and total activity were calculated by the formulas, relative activity/A 280 and specific activity x total OD, respectively, and expressed by the ratios to that of liver extract.
in the column and eluted by step-wise elution with buffers containing ethylene glycol and increasing concentrations of urea; about 60% of the activity was eluted by 6 M urea, with a 4.5-fold increase of specific activity. For further separation of the active protein(s), the 6 M urea fraction was applied to a Sephacryl S-200HR column ( Fig. 1 ). In this size exclusion chromatography, lipid A-inactivating activities were eluted in two peaks; one near the void volume and the other at the 170-kDa position together with a small peak of protein elution (A 280 ). SDS-PAGE analysis revealed that these fractions consisted of 25-100-kDa proteins with a uniform staining pattern (Fig. 1, inset) , suggesting that the active protein(s) likely have a tendency to aggregate with same or other molecules. Although a homogeneous protein fraction with lipid A-inactivating activity was not obtained, we noticed that the content of a 45-kDa protein was increased in these separation procedures; densitometric analysis of the SDS-PAGE gel revealed that the contents of a 45-kDa protein in the crude fraction and the 6 M urea fraction were 1/30.7 and 1/8.5, respectively. This increment nearly corresponded to the 4.5-fold increase of specific activity in the 6 M urea fraction (Table 1 ). This finding suggests that the 45-kDa protein might participate in lipid A-inactivation and prompted us to focus on the characterization of the 45-kDa protein in liver extract.
Identification of the 45-kDa protein from liver extract by amino acid sequencing
For molecular identification of the 45-kDa protein, we first subjected the 6 M urea fraction to SDS-PAGE and electroblotted proteins to a PVDF membrane. Ponceau S-stained spots corresponding to the 45-kDa protein were excised and analyzed by N-terminal Edman microsequencing, but no amino acid signals were obtained, presumably due to N-terminal blocking. We next excised and homogenized gels containing the 45-kDa protein and cleaved it with TPCK-trypsin or V8 protease. The cleaved products were analyzed by Tricine-SDS-PAGE (Fig. 2) . In a separate experiment, the gel was electroblotted onto a PVDF membrane and several bands well separated from others were excised, pooled and subjected to internal amino acid sequence analysis. While no amino acid signals were obtained from one of the three cleaved fragments analyzed, partial sequences were obtained from the other two fragments, which were identical with internal amino acid sequences (residues 192-206 and 281-283) of mouse argininosuccinate synthase (EC 6.3.4.5, Swiss-Prot/TrEMBL accession number: P16460, the total amino acid number 412), a rate-limiting enzyme in the urea-cycle ( Fig. 2 ). Mouse argininosuccinate synthase is a homotetrameric enzyme with a predicted monomeric molecular mass of 46.6 kDa and theoretical pI of 8.36. 30 The molecular weight (45 kDa) of the protein analyzed corresponded closely to the molecular mass of the protein and those of the fragments analyzed (23 kDa and 13 kDa) also nearly corresponded to the predicted molecular masses (25 kDa and 15 kDa) of C-terminal peptides when argininosuccinate synthase is cleaved at the sites cleaved by the enzymes used (Fig. 2) . The lack of detection of an N-terminal amino acid may be explained by N-terminal blocking of argininosuccinate synthase, which was reported in rat by Fengsrud et al. 31 In addition, the molecular mass of the homotetramer (186 kDa) corresponds closely to the estimated value (170 kDa) for the peak active fraction obtained by size exclusion chromatography, as shown in Figure 1 . Since we could assigned only 18 amino acids from two peptide fragments, to ascertain that the 45-kDa protein is argininosuccinate synthase, we cleaved argininosuccinate synthase purified as described below with proteases and obtained the same fragment patterns as shown in Figure 2 (data not shown).
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These results indicate that the major protein in the 6 M urea fraction with lipid A-inactivating activity is mouse argininosuccinate synthase.
Purification of argininosuccinate synthase from mouse liver
In an attempt to clarify possible interactions of argininosuccinate synthase with lipid A, we purified argininosuccinate synthase from mouse liver. Argininosuccinate synthase protein has previously been isolated from rats, 32 cattle, 33 and humans. 26 As no method for isolation of argininosuccinate synthase from mouse liver has been reported, we purified mouse argininosuccinate synthase referring to the methods for rat and human argininosuccinate synthase isolation. 26, 32 In each purification step, we evaluated the enzymatic activity as substrate-dependent pyrophosphate liberation from ATP by coupled enzyme reactions with addition of pyrophosphatase to the reaction mixture and the determination of inorganic phosphate (for details, see Materials and Methods).
Representative data of the purification of argininosuccinate synthase in 1 out of 3 independent experiments with essentially similar results are shown in Table 2 and SDS-PAGE analysis of each fraction is shown in Figure 3 . Although human argininosuccinate synthase was purified to homogeneity by the step corresponding to the S-300 fraction, the fraction from mouse contained several contaminating proteins (Fig. 3) . We, therefore, modified the procedure by adding anion-exchange HPLC as a final step of purification using UNO S-1. SDS-PAGE analysis of the active fractions eluted from UNO S-1 column by increasing the concentration of NaCl is also shown in Figure 3 . Fractions 12-14, where the mean concentration of NaCl was approximately 40 mM, were pooled and used as purified mouse argininosuccinate synthase. Densitometric analysis of the gel stained with CBB revealed at least 95% purity in the final fraction; Fig. 3 . SDS-PAGE analysis of fractions during purification of argininosuccinate synthase from mouse liver. The fractions shown in Table 2 the main contamination was a protein with a smaller molecular weight than argininosuccinate synthase, which was visible as a faint band in the front of argininosuccinate synthase (Fig. 3) . Analysis of the amino acid sequences of trypsin-cleaved products of the final fraction verified that the protein obtained was mouse argininosuccinate synthase (data not shown). Although the final step of purification increased the purity, the yield of protein was decreased, presumably due to adsorption to the matrix of the column. In this purification procedure, the final argininosuccinate synthase fraction showed about a 37-fold increase in the specific enzyme activity in comparison with liver homogenate supernatant ( Table 2 ). This value was in accordance with that for the purification of rat argininosuccinate synthase reported by Saheki et al. 32 but considerably lower than that for human argininosuccinate synthase purification. 26 The argininosuccinate synthase content in liver was estimated as about 1 mg/g wet liver by calculation from the values of total argininosuccinate synthase activity in the liver homogenate supernatant and the specific argininosuccinate synthase activity of purified argininosuccinate synthase. The value roughly equals that in normal human liver reported by Imamura et al. 34 Subsequently, we compared lipid A-inactivating activities between liver homogenate supernatant and the final argininosuccinate synthase fraction by estimating the protein concentration required for half inhibition (IC 50 ) of TNF-triggering activity of 40 ng/ml ONO-4007. As shown in Table 2 , the IC 50 value was decreased from 2.6 mg protein/ml to 79 µg protein/ml after the purification of argininosuccinate synthase. The increase of lipid A-inactivating activity was, therefore, estimated as 33-fold, which is very close to that of argininosuccinate synthase enzyme activity. These results indicate that argininosuccinate synthase is not the only, but a major, protein inactivating the biological activity of lipid A in mouse liver.
Among the biological activities of lipid A, the activation of Limulus amebocytes is highly sensitive, and the detailed structure of lipid A is responsible for this reaction. 35 ONO-4007 can trigger TNF production of Liver homogenate supernatant (LHS) obtained from 20 mice was subjected to ammonium sulfate precipitation and the active fractions were collected and subjected successively to several steps of liquid chromatography as described in Materials and Methods. Fractions from UNO S-1 chromatography were analyzed by SDS-PAGE ( Fig. 3) Figure 4 , argininosuccinate synthase inactivated both biological activities of LA-15-PP in a dose-dependent manner, indicating that argininosuccinate synthase inactivates the biological activities of lipid A generally.
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Differential inactivation of biological activities of lipid A and LPS by argininosuccinate synthase
To characterize the interaction of argininosuccinate synthase with lipid A and LPS further, we examined the effects of argininosuccinate synthase on natural lipid A and LPS. For this purpose, we tested distinct serotypes of LPS, smooth-type LPS (S-LPS) and rough-type LPS (R-LPS), in addition to monophosphoryl lipid A (MPL) and diphosphoryl lipid A (DPL) as targets of argininosuccinate synthase. Preliminary experiments showed that these LPS and lipid A species possessed divergent activities with regard to LAL activation and TNF-triggering, with R-LPS being most active and S-LPS, DPL and MPL following roughly in this order (data not shown), supporting previously documented findings. 35, 36 LPS and lipid A at concentrations around those causing a half-maximal response of LAL activation were incubated with increasing amounts of argininosuccinate synthase for 60 min, and the levels of LAL activation were compared; representative results from several experiments are shown in Figure 5A . The activities of R-LPS, DPL and MPL were inactivated by incubation with argininosuccinate synthase in a dose-dependent manner, while S-LPS was rather refractory to inactivation by argininosuccinate synthase. S-LPS was tested at a concentration of 200 pg/ml, which was 8-fold higher than the concentration of R-LPS used but comparable with that of MPL. In addition, LAL activation by S-LPS alone was indistinguishable from that by DPL alone.
Other experiments with lower concentration of S-LPS also showed refractoriness to argininosuccinate synthase (data not shown). These results indicate that argininosuccinate synthase hardly inactivates smooth-type LPS. We also examined the effects of argininosuccinate synthase on TNF-triggering by LPS and lipid A (Fig. 5B) . Argininosuccinate synthase inactivated the TNF-triggering activities of R-LPS, DPL and MPL in a dose-dependent fashion, but S-LPS was also refractory. In this case, the inactivating concentrations of argininosuccinate synthase were higher than those for LAL inactivation, presumably reflecting the fact that higher concentrations of LPS and lipid A are required for TNF-triggering stimulation than for LAL activation. In a separate experiment, LAL activation and TNF-triggering by S-LPS from E. coli O127:B8 were also refractory to argininosuccinate synthase at up to 100 µg/ml (data not shown). These results emphasize that argininosuccinate synthase preferentially inactivates lipid A and R-type LPS, which lack O-antigen, but fails to attenuate the smooth-type of LPS, which retains O-antigen.
Inhibition of argininosuccinate synthase enzyme activity by LPS and lipid A
If argininosuccinate synthase inactivates LPS and lipid A, one can expect that the enzyme activity of argininosuccinate synthase is likely suppressed by these molecules. We next examined this reverse interaction by measuring the change of argininosuccinate synthase enzyme activity after incubation with LPS and lipid A. As shown in Figure 6 , Sand R-LPS and lipid A, including a synthetic derivative, inhibited the activity of argininosuccinate synthase in a dose-dependent manner. The concentrations for half inhibition of argininosuccinate synthase enzyme activity were roughly estimated as 24, 230, 270, 39, and 6.5 µg/ml for S-LPS, R-LPS, MPL, DPL and ONO-4007, respectively. In this case, S-LPS inhibited argininosuccinate synthase activity more efficiently than R-LPS did (about 10-fold). Differences in the inhibitory efficiencies of lipid A molecules were also observed. Since we used a coupled enzyme reaction to measure argininosuccinate synthase enzymatic activity by the addition of excess pyrophosphatase, we examined the direct effects of LPS and lipid A on pyrophosphatase activity using pyrophosphate as a substrate. However, no inhibitory effects were observed even at the highest concentrations of lipid A and LPS indicated in Figure 6 (data not shown). Although the molecular basis for these divergent strengths of LPS and lipid A inhibition was not clear, these results support the notion that argininosuccinate synthase is able to interact with LPS and lipid A, including S-LPS.
Assessment of argininosuccinate synthase association with lipid A and LPS by native/SDS 2-D PAGE
Physical association of argininosuccinate synthase with lipid A and LPS was analyzed by detecting the formation of complexes consisting of argininosuccinate synthase and lipid A or LPS in native polyacrylamide gel electrophoresis (native PAGE), essentially according to the method described by Kusunoki et al. 37 Since the theoretical pI for mouse argininosuccinate synthase was estimated as 8. 35 and those for rat and human argininosuccinate synthase were measured to be around 8.0, 26, 38 it was expected that native mouse argininosuccinate synthase would be unable to enter the gel in the direction of the cathode at lower pH of the sample buffer (pH 7.5). In fact, no bands were detected in the gel after electrophoresis of argininosuccinate synthase alone (Fig.  7A,B ). If argininosuccinate synthase associates with molecules possessing negative charges in this experimental condition, one can assume that protein bands corresponding to argininosuccinate synthase should be detected together with associating molecules in native PAGE. As shown in Figure 7A , LPS or lipid A alone migrated as smeared bands with various staining intensities, which may be explained by the aggregated forms of these molecules, as documented before 39 and different reactivities with silver reagent due to a varied content of oligosaccharide chains. Incubation with argininosuccinate synthase at 37°C for 30 min shifted the bands of LPS and lipid A completely to higher molecular weight positions. The patterns and intensities of the image were different according to the types of LPS and lipid A, and were dependent on their concentrations. To detect the existence of argininosuccinate synthase in the native PAGE bands of argininosuccinate synthase and LPS or lipid A mixtures, the bands were analyzed by Western blotting with anti-argininosuccinate synthase antiserum. As shown in Figure 7B , the bands from LPS plus argininosuccinate synthase or lipid A plus argininosuccinate synthase mixture were stained with anti-argininosuccinate synthase antiserum, indicating the presence of argininosuccinate synthase molecules in these bands.
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To clarify further whether lipid A and LPS co-migrate with argininosuccinate synthase molecules, gel slices were cut from a native PAGE gel and analyzed by further SDS-PAGE (native/SDS 2-D PAGE). As shown in Figure 8A , S-LPS not treated with argininosuccinate synthase migrated in several bands with various molecular masses in SDS-PAGE, which may suggest the molecular diversity of O-side chains of this molecule, as indicated by others. 40 R-LPS alone migrated at the front position under these SDS-PAGE conditions (Fig. 8B) . Both DPL and MPL were more rapidly electrophoresed, owing to the smaller molecular mass of these molecules, which possess neither O-side chains nor core oligosaccharides (Fig. 8C,D) . As expected from the Western blotting analysis of native PAGE of argininosuccinate synthase plus LPS or lipid A (Fig. 7B) , the smeared bands in the native PAGE were separated into argininosuccinate synthase (large arrowhead: 45 kDa) and LPS or lipid A (small arrowheads; Fig. 8A-D) . Western blotting with anti-argininosuccinate synthase antiserum stained only the argininosuccinate synthase bands indicated in Fig. 7 . Analysis of the interaction of mouse argininosuccinate synthase with lipid A or LPS by native PAGE. Argininosuccinate synthase (final 10 µg/ml) was mixed with S-LPS, R-LPS, LPS-K12 or DPL (20 µg/ml) or MPL (40 µg/ml). After incubation at 37°C for 30 min, a 30-µl portion of the mixture was analyzed by native PAGE and the gel was silver-stained (A) or the transblotted membrane was stained with anti-argininosuccinate synthase antiserum (B). Figure 8A -D (data not shown). It is noteworthy that the positions of argininosuccinate synthase, LPS and lipid A migrating in SDS-PAGE were not changed even after incubation with each other, regardless of the different migration patterns in native PAGE. This evidence supports the idea that argininosuccinate synthase associates with these molecules without degrading them to inactive forms. In addition, although argininosuccinate synthase preparation contained a small amount of contaminating protein with a smaller molecular size than argininosuccinate synthase (Fig. 3) , native/SDS 2-D PAGE revealed that only argininosuccinate synthase co-migrated with lipid A and LPS. These results indicate that argininosuccinate synthase can physically bind LPS in a stable form, and lipid A is the binding moiety for argininosuccinate synthase association.
Analysis of argininosuccinate synthase association with 3 H-LPS by immunoprecipitation
Finally, we further verified the association of argininosuccinate synthase and LPS, by analyzing the complex formation of argininosuccinate synthase and [ 3 H]-labeled LPS by immunoprecipitation with antiargininosuccinate synthase rabbit antiserum and protein G-Sepharose. Before carrying out this experiment, we checked the inhibitory effects of LPS and lipid A on the binding of anti-argininosuccinate synthase IgG to argininosuccinate synthase immobilized on a microtiter plate by ELISA. Addition of up to 20 µg/ml of S-and R-LPS or DPL to argininosuccinate synthase-coated wells failed to affect the dose-dependent binding of antiargininosuccinate synthase IgG onto the wells, indicat- ing that LPS and lipid A do not interfere with the binding of anti-argininosuccinate synthase antibody to argininosuccinate synthase (data not shown). As shown in Figure  9A , 3 H-LPS was significantly precipitated by consecutive pre-incubation with argininosuccinate synthase and anti-argininosuccinate synthase antiserum. Treatment with pre-immune serum failed to precipitate 3 H-LPS at all. 3 H-LPS treated with anti-argininosuccinate synthase antiserum alone was not precipitated. These results indicate that argininosuccinate synthase and LPS firmly associate in a complex form in liquid phase. To examine argininosuccinate synthase and LPS association in the crude liver extract, we next examined if anti-argininosuccinate synthase antiserum precipitates 3 H-LPS treated with the liver cytosol fraction (Fig. 9B) . The amount of argininosuccinate synthase in the liver cytosol fraction was measured by its enzyme activity and estimated as 90 µg/ml in the mixture. Although the effi-ciency was lower than that of the purified argininosuccinate synthase plus 3 H-LPS combination, 3 H-LPS was recovered by anti-argininosuccinate synthase antibody from the liver cytosol plus 3 H-LPS combination. The reason for the low recovery of 3 H-LPS from the clued liver cytosol by anti-argininosuccinate synthase antibody is obscure. One possible explanation may be the existence of factors in the cytosol interfering the antigen-antibody interaction or protein G binding. Nevertheless, these results suggesting that argininosuccinate synthase is not the only constituent, but is an effective constituent that can bind LPS in liver cytosol.
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DISCUSSION
In the present study, sequencing a protein enriched in a partially purified fraction with lipid A-inactivating activity 34 Satoh, Iwahori, Sugawara, Yamazaki from mouse liver cytosol, we unexpectedly found that the protein is a rate-limiting enzyme in the urea cycle, argininosuccinate synthase, which catalyzes the reversible ATP-dependent ligation of citrulline and aspartate to generate argininosuccinate. To ascertain whether argininosuccinate synthase interacts with and inactivates lipid A, we isolated argininosuccinate synthase from mouse liver cytosol by measuring its enzymatic activity together with its lipid A inactivating activity, and found that both activities increased essentially in a parallel fashion ( Table 2 ). The purified argininosuccinate synthase fraction inactivated two well-characterized biological activities of synthetic lipid A -macrophage activation and LAL activation (Fig. 4) . Therefore, the protein(s) that was previously reported by us to inactivate the biological activity of lipid A in mouse liver 25 was mainly, if not exclusively, argininosuccinate synthase.
Lipid A is the endotoxic-principal portion of LPS and the intensity and specificity of its biological activities are determined by its structure. 36 The rest of LPS is composed of a large divergent polysaccharide chain (O-side chain) and largely invariable core oligosaccharides, which are also known to influence LPS bioactivities. 36 Smooth types of LPS (S-LPS) possess all three portions, while rough-type mutants of LPS lack O-antigen but retain lipid A with progressively shorter core oligosaccharides. Very recent publications show that the bioactive unit of lipid A and LPS is the aggregate form and the monomeric form possesses no activity. 41 To examine the preference of argininosuccinate synthase action for structurally different LPS and lipid A molecules, we compared the inhibitory strengths of argininosuccinate synthase against macrophage and LAL activation of Sand R-LPS and diphosphoryl and monophosphoryl lipid A (DPL and MPL; Fig. 5A,B) . The results demonstrated that both activities of R-LPS and lipid A were susceptible to suppression by argininosuccinate synthase, whereas those of S-LPS were relatively refractory to argininosuccinate synthase. The difference in sensitivity to argininosuccinate synthase among S-LPS and R-LPS or lipid A might be explained simply by the inability of argininosuccinate synthase binding to S-LPS, e.g. by steric constraints due to the large O-side chain polysaccharide of S-type LPS. However, this does not seem to be the case since the association of argininosuccinate synthase with S-LPS was evident. First, not only R-LPS and lipid A inhibited the enzymatic activity of argininosuccinate synthase in a dose-dependent fashion, but S-LPS also did with an apparently high intensity (Fig. 6) . These findings clearly imply that LPS, including S-LPS, can bind to argininosuccinate synthase. Additional evidence for the association of argininosuccinate synthase with lipid A and LPS, including S-LPS, was provided by a native gel electrophoresis experiment (Fig. 7) .
Amphiphilic properties render these molecules prone to self-associate and form large macromolecular structures (micelles) in aqueous conditions, which is revealed by a broad peak on size-exclusion chromatography 17, 39 or a broad band in electrophoresis under native conditions, 13, 37 as observed in the present study. The quantities and acidic properties of O-side chain polysaccharides or the core region of LPS as well as the concentration of divalent cations in the solution are responsible for determining the molecular mass of the micelle. Physical binding of proteins to the micelles may simply enlarge the size of micelles or reduce the tendency of the micelles to disaggregate, conceivably depending upon the nature of associating proteins. 39 The findings that, in the presence of argininosuccinate synthase, broad bands of LPS and lipid A shifted to high-molecular-weight positions where argininosuccinate synthase co-migrated support the idea that argininosuccinate synthase binds to, and forms a stable complex with, the micelles of lipid A and LPS. More direct evidence was obtained from native/SDS 2-D PAGE analysis, which showed an association of argininosuccinate synthase with S-LPS as well as R-LPS, DPL and MPL (Fig. 8) . A stable association of argininosuccinate synthase with R-LPS was also demonstrated by immunoprecipitation with anti-argininosuccinate synthase antiserum, using [ 3 H]-labeled R-LPS ( Fig. 9) . These results suggest that physical association is not sufficient for inactivation of S-LPS biological activities by argininosuccinate synthase. It is uncertain why the binding of argininosuccinate synthase to S-LPS failed to suppress its biological activity, while R-LPS and lipid A were efficiently inactivated by argininosuccinate synthase. A possible explanation may be a lower amount of argininosuccinate synthase incorporation into the micelles composed of S-LPS than those composed of R-LPS and lipid A. Less efficient binding to S-LPS than R-LPS and lipid A was reported in the association of lactoferrin with those molecules by Caccavo et al. 42 Those authors explained this finding by steric hindrance exerted by the relatively large O-side chain and the core structure. Quantitative analyses of argininosuccinate synthase binding to the micelles, which was not done in the present study, would be required to test this idea. The refractoriness of S-LPS to argininosuccinate synthase might be alternatively explained by the molecular heterogeneity in S-LPS preparation. Jiao et al. 43 reported that S-LPS preparation consisted of Ra-and Rb-form LPS and O-chain-containing LPS. The latter species was characterized by lipid A molecules of reduced fatty acid content. Underacylated lipid A species exhibit almost no endotoxic activity and act as antagonists in a homogeneous aggregate form. However, when they form aggregates mixed with agonistic lipid A in a optimal proportion, they enhance the biological activity of the latter. 41 Thus, it is possible that argininosuccinate synthase may bind underacylated lipid A constituents in the current S-LPS preparation and this interaction might musk the inactivation of the total bioactivity of S-LPS by argininosuccinate synthase.
There are several proteins and peptides that are able to bind LPS and have been well characterized with regard to the regions required for binding to LPS and lipid A. LPS-binding protein (LBP), 44 bactericidal/permeability increasing protein (BPI), 9 CAP-18 10 and Limulus anti-LPS factor (LALF) 45 all possess primary structures with a stretch of about 30-40 amino acids containing cationic and hydrophobic amino acid clusters, which are thought to be involved in the interaction with the lipid A portion of LPS via both ionic and hydrophobic interactions. Surfactant protein A (SP-A) and surfactant protein D (SP-D), which both belong to the collectin subgroup of the C-type lectin superfamily, bind preferentially to rough-type LPS in a Ca 2+ -dependent manner and via a lectin-like interaction. 16 Another structurally different component of lung surfactant, surfactant protein C (SP-C), which is a hydrophobic peptide composed of 34-35 amino acids with 2 cysteine-linked palmitoyl residues, binds to LPS via an interaction between phosphoryl groups of lipid A and the N-terminal cationic region of the protein as well as acyl chains and C-terminal hydrophobic regions. 46 It was also reported that hemoglobin binds LPS and enhances its macrophage stimulation, while heme-free globin also binds LPS but attenuates the biological activity of LPS, 13 although the precise binding region of globin has not yet been identified. Lactoferrin was reported to modulate LPS activity, and cationic amino acid clusters in residues 1-5 and 28-34 are responsible for the binding to LPS 11 and IL-8 binding to proteoglycans. 47 The relatively tight binding of argininosuccinate synthase to Phenyl-cellulofine (Table 1) implies that argininosuccinate synthase likely binds to both LPS and lipid A via hydrophobic interaction with the acyl chains of lipid A. The basic property of argininosuccinate synthase, as reflected by its high pI, 26 also possibly allows an ionic interaction with phosphoryl groups and acidic saccharide moieties of LPS. The amino acid sequence of mouse argininosuccinate synthase 30 indicates several candidate regions containing clusters of cationic and hydrophobic amino acids. Analysis of the role of peptide fragments derived from argininosuccinate synthase in its LPS-binding activity is now underway in our laboratory.
The biological role of argininosuccinate synthase in the liver in detoxification and clearance of circulating LPS remains to be clarified. In addition, the pathological significance of the inhibitory action of LPS on argininosuccinate synthase enzymatic activity is obscure. Although a precise explanation of the protective role of argininosuccinate synthase in LPS hypersensitivity is not possible at this time, some speculation is possible.
The expression of argininosuccinate synthase is mostly restricted to the liver and kidney in the adult animal. 48 Argininosuccinate synthase was initially recognized as a urea cycle component in the hepatocyte cytosol. In the kidney, together with the second urea cycle enzyme, argininosuccinate lyase, argininosuccinate synthase functions to generate arginine from citrulline and aspartate and release it into the bloodstream. 49 In addition to the nitrogen metabolism and de novo synthesis of arginine, a crucial role for argininosuccinate synthase is now recognized in the regulation of vasodilation and inflammatory responses under pathological conditions; this effect involves sustaining the generation of nitric oxide (NO). NO is synthesized by nitric-oxide synthase (NOS) from arginine present in the cytosolic pool or transported from the plasma. Argininosuccinate synthase and argininosuccinate lyase together recycle citrulline generated by NOS from arginine to arginine (citrulline-NO cycle). 50, 51 The expression of argininosuccinate synthase together with argininosuccinate lyase and inducible NOS (iNOS) is induced by pharmacological stimulation, physical stress and inflammation in many types of tissues and cells, including endothelial cells. [52] [53] [54] In the present study, we showed that both LPS and lipid A possess the ability to inhibit the enzymatic activity of argininosuccinate synthase. To the best of our knowledge, argininosuccinate synthase inhibition by endotoxin has not previously been reported. Our findings indicate the possibility that bacterial products might potentially regulate the arginine metabolism in the host and perturb NO synthesis, especially at the site of bacterial infection.
Whether argininosuccinate synthase functions in the liver to eliminate circulating LPS remains to be clarified. It has been reported that hepatocytes internalize LPS via LDL receptor and LRP and excrete it to the bile. [19] [20] [21] Flam et al. 55 reported that a considerable amount of argininosuccinate synthase localizes in the caveolar region of the endothelial cell membrane, indicating the dynamic translocation of argininosuccinate synthase in the intracellular compartments from the cytosol to the membrane. It is conceivable that argininosuccinate synthase might participate in this intracellular LPS transport in direct or indirect ways together with other molecular components. Experiments in in vitro cultures of hepatocytes would clarify the role of argininosuccinate synthase in LPS excretion by the cells. Recently developed methods of hepatocyte spheroid culture were reported to sustain various cellular functions of hepatocytes efficiently, including the excretion of bile. 56 Therefore, this culture system will likely be useful to elucidate the role of argininosuccinate synthase in hepatocyte LPS clearance and we are now undertaking experiments using hepatocyte spheroid cultures.
Another possible role of argininosuccinate synthase in interacting with LPS may occur in the circulating blood.
Hepatic damage due to viral infection, autoimmunity and hepatotoxic chemicals coincides with leakage of cytosolic proteins of hepatocytes. Argininosuccinate synthase has been reported to emerge in the blood stream during hepatitis in humans. 57 The content of argininosuccinate synthase in mouse liver was roughly estimated as 1-2 mg per liver in this study and we also observed that hepatic damage induced by chemicals promoted the leakage of a considerable amount of argininosuccinate synthase from the liver to the blood (data not shown). Although hepatic damage and total loss of hepatocyte function may result in a decrease of LPS clearance from the circulation, one can speculate that argininosuccinate synthase leaked from hepatocytes may interact with LPS in the blood and repress its stimulatory activity, consequently compensating for the loss in liver LPS clearance.
Finally, we found that argininosuccinate synthase physically interacts with LPS and its biologically active moiety, lipid A, and inhibits some biological activities of LPS, especially of R-LPS and lipid A. Identification of the LPS-binding portions of argininosuccinate synthase should be useful in the design of small peptides that would impede LPS activity.
